EQS-Ad-hoc: CompuGroup Medical SE & Co. KGaA / Key word(s): Dividend The general partner and the supervisory board of CompuGroup Medical SE & Co. KGaA (the „Company“) (ISIN: DE000A288904 | WKN: A28890) intend to propose to the annual general meeting that only the legally required minimum shall be paid out as dividend for the financial year 2024. This would result in a distribution of EUR 0.05 per dividend bearing share (previous year: EUR 1.00), assuming an unchanged amount of treasury shares. The proposal is made against the backdrop of the Company’s long-term innovation and growth strategy, including investments in infrastructure and resources for greater proximity to customers as well as AI-based processes and products. It further considers, based on the prepared consolidated financial statements, the development of revenue and profitability in the financial year 2024 in line with the adjusted full-year forecast. According to the prepared consolidated financial statements, the Company generated revenues of approx. EUR 1.154 billion in the financial year 2024 (previous year: approx. EUR 1.188 billion). The organic revenue decreased by around two per cent year-on-year. Adjusted EBITDA decreased by around 15 per cent to approx. EUR 224.6 million (previous year: approx. EUR 264.8 million). The adjusted earnings per share amounted to approx. EUR 1.27 (previous year: approx. EUR 2.06). A dividend payment based on the final dividend proposal of the general partner and the supervisory board for the financial year 2024 is subject to the approval by the annual general meeting, which is expected to be held in August 2025, as well as further legal requirements. CompuGroup Medical SE & Co. KGaA will publish the full annual report for the financial year 2024 as planned on March 6, 2025. “Adjusted EBITDA” and “adjusted earnings per share” are defined in the annual report for the financial year 2023 on p. 45 et seq. End of Inside Information
04-March-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | CompuGroup Medical SE & Co. KGaA |
Maria Trost 21 | |
56070 Koblenz | |
Germany | |
Phone: | +49 (0)160 3630362 |
Fax: | +49 (0)261 8000 3200 |
E-mail: | investor@cgm.com |
Internet: | www.cgm.com |
ISIN: | DE000A288904 |
WKN: | A28890 |
Indices: | SDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2095063 |
End of Announcement | EQS News Service |
|
2095063 04-March-2025 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.